ASX-listed Neurotech International has announced the expansion of its exclusive licence with Dolce Cann Global to include all neurological disorders, specifically autism, epilepsy, ADHD, alzheimer’s disease, huntington’s disease, multiple sclerosis, transverse myelitis, inflammatory brain disease, fibromyalgia, chronic fatigue and migraine.
Neurotech said latest clinical research shows inflammation, and more specifically neuroinflammation, is a well-recognised common feature in all neurological disorders.
It said based on scientific data generated to date, and unlike CBD alone, NTI/Dolce full-spectrum medicinal cannabis strains have powerful, neuro-modulatory, anti-inflammatory and neuro-regulatory mode of action.
The global market for neurology treatments is expected to grow to $39.4 billion by 2024 driven by the rising prevalence of neurological diseases and increasing awareness associated with the disease diagnosis in developing countries.
Chairman of Neurotech International Brian Leedman said: “The amendment of the Dolce Cann Global licence provides scope for the company to expand our research programs beyond the current program with its focus on autism in children that is due to commence later this month.”